phosphorylcholine has been researched along with Carcinoma, Non-Small Cell Lung in 12 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition, at the highest dosage group in rats, an increase in white blood cell counts (WBC) was observed." | 2.67 | Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine. ( Drogendijk, TE; Oosterom, R; Planting, AS; Pronk, LC; Stoter, G; Verweij, J, 1994) |
| " In vivo, we further revealed that the chronic administration of low-doses of paclitaxel - i." | 1.46 | Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression. ( André, N; Berges, R; Borge, L; Bourgarel, V; Braguer, D; Buric, D; Carré, M; Carrier, A; Le Grand, M; Montero, MP; Pasquier, E; Vasseur, S, 2017) |
| "Perifosine is an orally bioavailable alkylphospholipid currently being tested in phase II clinical trials as a potential anticancer drug." | 1.35 | Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism. ( Elrod, HA; Khuri, FR; Sun, SY; Yue, P, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Le Grand, M | 1 |
| Berges, R | 1 |
| Pasquier, E | 1 |
| Montero, MP | 1 |
| Borge, L | 1 |
| Carrier, A | 1 |
| Vasseur, S | 1 |
| Bourgarel, V | 1 |
| Buric, D | 1 |
| André, N | 1 |
| Braguer, D | 1 |
| Carré, M | 1 |
| Wu, DW | 1 |
| Lee, MC | 1 |
| Hsu, NY | 1 |
| Wu, TC | 1 |
| Wu, JY | 1 |
| Wang, YC | 1 |
| Cheng, YW | 1 |
| Chen, CY | 1 |
| Lee, H | 1 |
| Yue, H | 1 |
| Li, W | 1 |
| Liu, P | 1 |
| Gao, J | 1 |
| Miao, J | 1 |
| Zhao, J | 1 |
| Srinual, S | 1 |
| Chanvorachote, P | 1 |
| Pongrakhananon, V | 1 |
| Elrod, HA | 2 |
| Yue, P | 2 |
| Khuri, FR | 2 |
| Sun, SY | 2 |
| Ma, Z | 1 |
| Zhu, L | 1 |
| Luo, X | 1 |
| Zhai, S | 1 |
| Li, P | 1 |
| Wang, X | 2 |
| Yu, H | 1 |
| Zou, Y | 1 |
| Jiang, L | 1 |
| Yin, Q | 1 |
| He, X | 1 |
| Chen, L | 1 |
| Zhang, Z | 1 |
| Gu, W | 1 |
| Li, Y | 1 |
| Pinchuk, AN | 1 |
| Rampy, MA | 1 |
| Longino, MA | 1 |
| Skinner, RW | 1 |
| Gross, MD | 1 |
| Weichert, JP | 1 |
| Counsell, RE | 1 |
| Lin, YD | 1 |
| Lonial, S | 1 |
| Glunde, K | 1 |
| Bhujwalla, ZM | 1 |
| Pronk, LC | 1 |
| Planting, AS | 1 |
| Oosterom, R | 1 |
| Drogendijk, TE | 1 |
| Stoter, G | 2 |
| Verweij, J | 2 |
| Planting, A | 1 |
| van der Burg, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
2 trials available for phosphorylcholine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, | 1994 |
A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colore | 1992 |
10 other studies available for phosphorylcholine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; | 2017 |
FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction.
Topics: Acid Anhydride Hydrolases; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis | 2015 |
Inhibition of autophagy promoted sphingosylphosphorylcholine induced cell death in non-small cell lung cancer cells.
Topics: Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Humans; Lung Neoplasms; Phos | 2014 |
Suppression of cancer stem-like phenotypes in NCI-H460 lung cancer cells by vanillin through an Akt-dependent pathway.
Topics: AC133 Antigen; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Benzaldehydes; Carcinoma, No | 2017 |
Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism.
Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; | 2009 |
Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Gene Knockdown Techniques; Glycog | 2012 |
Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Pr | 2013 |
Synthesis and structure-activity relationship effects on the tumor avidity of radioiodinated phospholipid ether analogues.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Humans; Iodine Radioisotopes; Kid | 2006 |
The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; CASP8 and FADD-Like Apoptosis Regu | 2007 |
Choline kinase alpha in cancer prognosis and treatment.
Topics: Carcinoma, Non-Small-Cell Lung; Choline; Choline Kinase; Humans; Lung Neoplasms; Magnetic Resonance | 2007 |